Everspin's Microchip Pact Boosts On-Shore Capacity but Fails to Alter Rich Valuation Concerns

What happened

Everspin Technologies announced a 10-year manufacturing agreement with Microchip Technology to expand on-shore MRAM production capacity, aiming to secure long-term supply for strategic markets like automotive and defense. This move aligns with the company's focus on high-reliability applications, including the DoD award and automotive-grade PERSYST MRAM, potentially supporting future growth. However, the agreement likely involves fixed commitments that could strain Everspin's $45.3 million cash balance or increase operational leverage, posing risks if demand growth falters. Despite management's optimistic portrayal, the company's history of revenue volatility and recent net losses underscores the challenge of converting capacity into consistent profitability. Investors must scrutinize this expansion against the stock's elevated 119x EV/EBITDA multiple, which already discounts near-perfect execution towards doubling revenue.

Implication

The partnership with Microchip could enhance Everspin's ability to meet demand from key sectors like defense and automotive, supporting revenue growth if design wins scale. However, it may lead to increased capital expenditures or dependency on a single manufacturing partner, potentially eroding the net-cash advantage that provides downside protection. Everspin's lumpy licensing income and variable product sales mean that capacity expansion alone won't guarantee the sustained mid-teens growth needed to justify current valuations. With the stock trading at $14.81, above most analyst targets, and insider selling noted, investors should be wary of over-optimism embedded in the price. Therefore, while the news is a positive operational step, it doesn't change the recommendation to wait for a pullback or clearer evidence of fundamental acceleration before investing.

Thesis delta

The manufacturing agreement with Microchip reinforces Everspin's commitment to on-shore production and could support growth in key segments like automotive and defense. However, it doesn't materially change the risk/reward profile, as the core challenges of high valuation, lumpy revenue, and execution risks remain. Investors should still await either a price correction to ~$9-$10 or demonstrable improvements in revenue and margins before considering a more bullish stance.